Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S Kittai, David Bond, Ying Huang, et al.Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.The Lancet. Haematology|September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.Blood Cancer Journal|December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaFarhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.Cancer Cell|September 24, 2019
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Vivian M Liu, Daniel Rosebrock, et al.Pageof 7